1. Home
  2. GNTA vs BOLD Comparison

GNTA vs BOLD Comparison

Compare GNTA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNTA
  • BOLD
  • Stock Information
  • Founded
  • GNTA 2014
  • BOLD 2018
  • Country
  • GNTA Italy
  • BOLD United States
  • Employees
  • GNTA N/A
  • BOLD N/A
  • Industry
  • GNTA Biotechnology: Biological Products (No Diagnostic Substances)
  • BOLD
  • Sector
  • GNTA Health Care
  • BOLD
  • Exchange
  • GNTA Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • GNTA 81.2M
  • BOLD 30.3M
  • IPO Year
  • GNTA 2021
  • BOLD 2024
  • Fundamental
  • Price
  • GNTA N/A
  • BOLD $1.07
  • Analyst Decision
  • GNTA Strong Buy
  • BOLD Buy
  • Analyst Count
  • GNTA 1
  • BOLD 3
  • Target Price
  • GNTA $25.00
  • BOLD $4.00
  • AVG Volume (30 Days)
  • GNTA 29.4K
  • BOLD 363.5K
  • Earning Date
  • GNTA 01-01-0001
  • BOLD 08-11-2025
  • Dividend Yield
  • GNTA N/A
  • BOLD N/A
  • EPS Growth
  • GNTA N/A
  • BOLD N/A
  • EPS
  • GNTA N/A
  • BOLD N/A
  • Revenue
  • GNTA N/A
  • BOLD N/A
  • Revenue This Year
  • GNTA N/A
  • BOLD N/A
  • Revenue Next Year
  • GNTA N/A
  • BOLD N/A
  • P/E Ratio
  • GNTA N/A
  • BOLD N/A
  • Revenue Growth
  • GNTA N/A
  • BOLD N/A
  • 52 Week Low
  • GNTA $2.74
  • BOLD $1.00
  • 52 Week High
  • GNTA $7.28
  • BOLD $4.72
  • Technical
  • Relative Strength Index (RSI)
  • GNTA 54.55
  • BOLD N/A
  • Support Level
  • GNTA $2.74
  • BOLD N/A
  • Resistance Level
  • GNTA $3.94
  • BOLD N/A
  • Average True Range (ATR)
  • GNTA 0.29
  • BOLD 0.00
  • MACD
  • GNTA 0.08
  • BOLD 0.00
  • Stochastic Oscillator
  • GNTA 88.33
  • BOLD 0.00

About GNTA Genenta Science S.p.A.

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: